Last reviewed · How we verify
Geneserine (ESERIDINE)
Geneserine (generic name: ESERIDINE) is a eseridine drug. It is currently in Phase 2 development for Indigestion.
Geneserine works by inhibiting the enzyme cholinesterase, which breaks down the neurotransmitter acetylcholine.
Geneserine (Eseridine) is a small molecule drug that targets cholinesterase, a key enzyme involved in neurotransmission. It is used to treat indigestion, a condition characterized by discomfort or pain in the upper abdomen. The commercial status of Geneserine is unclear, and it is not known whether it is patented or available as a generic medication. As a cholinesterase inhibitor, Geneserine works by increasing the levels of acetylcholine in the body, a neurotransmitter that helps to regulate various bodily functions. However, more information is needed to fully understand its clinical use and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ESERIDINE |
|---|---|
| Drug class | eseridine |
| Target | Cholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of acetylcholine like a key that unlocks certain functions in the body. When cholinesterase breaks it down, the key is removed, and those functions are turned off. By blocking cholinesterase, Geneserine allows more acetylcholine to be available, effectively keeping the key in the lock and allowing those functions to continue.
Approved indications
- Indigestion
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Geneserine CI brief — competitive landscape report
- Geneserine updates RSS · CI watch RSS
Frequently asked questions about Geneserine
What is Geneserine?
How does Geneserine work?
What is Geneserine used for?
What is the generic name of Geneserine?
What drug class is Geneserine in?
What development phase is Geneserine in?
What does Geneserine target?
Related
- Drug class: All eseridine drugs
- Target: All drugs targeting Cholinesterase
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Indigestion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing